ArticleScientific reports2026
CLEIA-based type IV collagen 7S for second-step assessment of MRE-defined clinically significant fibrosis in MASLD with indeterminate FIB-4.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Stepwise MASLD pathways based on the fibrosis-4 (FIB-4) index leave a large indeterminate subgroup requiring second-step assessment. We evaluated automated chemiluminescent enzyme immunoassay (CLEIA)-based type IV collagen 7S (COL4-7S) as a candidate second-line test for MRE-defined clinically significant fibrosis (≥F2). In this retrospective derivation-validation study, adults with MASLD underwent clinically indicated magnetic resonance elastography (MRE) with serum biomarkers measured within 30 days in a two-center derivation cohort (n=347) and an independent external validation cohort (n=126). COL4-7S was compared with ELF, M2BPGi, and FIB-4 using MRE-defined fibrosis stage (F0-F4). In the derivation cohort, MRE liver stiffness correlated with COL4-7S (r=0.59), ELF (r=0.58), M2BPGi (r=0.62), and FIB-4 (r=0.49; all p<0.001), with similar ordinal discrimination across F0-F4. Within the indeterminate FIB-4 range, second-step COL4-7S correctly classified 90/136 patients (66%) for MRE-defined ≥F2; ELF and M2BPGi correctly classified 90/136 (66%) and 73/136 (54%), respectively. In external validation, COL4-7S and ELF correctly classified 32/50 (64%) and 34/50 (68%) patients, respectively. These findings indicate numerically similar second-step performance of CLEIA-based COL4-7S and ELF for MRE-defined ≥F2 fibrosis in this retrospective cohort. Prospective studies are needed to determine whether COL4-7S improves workflow, cost-effectiveness, and patient outcomes in routine MASLD pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.